Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving Prospects for Targeting RAS.

Harshabad Singh1, Dan L Longo1, Bruce A Chabner2

  • 1Harshabad Singh and Bruce A. Chabner, Massachusetts General Hospital Cancer Center; Harshabad Singh, Dana-Farber Cancer Institute; and Dan L. Longo, Brigham and Women's Hospital, Boston, MA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 16, 2015
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biochemistry at scale: Seeing both the forest and the trees.

Trends in biochemical sciences·2026
Same author

Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence.

NPJ precision oncology·2026
Same author

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Nature cancer·2026
Same author

Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancer.

Cancer cell·2026
Same author

Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification.

medRxiv : the preprint server for health sciences·2026
Same author

The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Targeting RAS mutations in cancer, long a challenge, is now advancing with new direct inhibitors and synthetic lethality approaches. Research shows promise for novel therapies against these common cancer drivers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • RAS mutations are prevalent oncogenic drivers in human cancers, present in approximately one-third of solid tumors and one-fifth of myeloid malignancies.
  • Despite decades of research, targeting these RAS mutations therapeutically has remained a significant challenge.
  • Recent breakthroughs in understanding RAS structure, function, and signaling have opened new therapeutic avenues.

Purpose of the Study:

  • To review current and emerging therapeutic strategies targeting mutant RAS proteins.
  • To highlight the significance of recent developments in direct RAS inhibition.
  • To discuss the ongoing clinical trials and future directions for RAS-targeted therapies.

Main Methods:

  • Review of recent scientific literature and clinical trial data.

Related Experiment Videos

  • Analysis of novel inhibitor development for RAS processing and signaling pathways.
  • Discussion of drug-like property refinement for clinical translation.

    • Main Results:

    • The development of direct RAS inhibitors, particularly for KRAS G12C mutations, marks a significant advancement.
    • Multiple clinical trials are actively investigating therapies targeting synthetic lethal partners or downstream effectors of RAS.
    • Laboratory studies show encouraging results for novel inhibitors targeting various aspects of RAS processing and signaling.

    Conclusions:

    • Mutant RAS proteins are becoming increasingly druggable, shifting therapeutic paradigms.
    • Further refinement of drug-like properties is necessary for the clinical readiness of novel RAS-targeting agents.
    • Targeting RAS mutations holds significant promise for future cancer treatment strategies.